SCHEMBL1122090

SCHEMBL1122090

Clc1cncc(Oc2ccccc2Cl)n1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.58
HTT P42858 1/20 0.58
KMT2A Q03164 1/20 0.46
IDO1 P14902 1/20 0.42
MAP4K4 O95819 1/20 0.42
NTRK1 P04629 1/20 0.39
CDK2 P24941 2/20 0.39
PTGS1 P23219 2/20 0.38
PTGS2 P35354 2/20 0.38
BLM P54132 1/20 0.38
LMNA P02545 2/20 0.38
HPGD P15428 1/20 0.38
HRH3 Q9Y5N1 2/20 0.37
SLC6A2 P23975 3/20 0.37
SLC6A4 P31645 3/20 0.37
SLC6A3 Q01959 3/20 0.37
CXCL8 P10145 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1122296 0.83 BRAF (0.49) ALDH1A1HTTKMT2AMAP4K4NTRK1
SCHEMBL958698 0.78 ALDH1A1 (0.53) ALDH1A1HTTKMT2AIDO1MAP4K4
SCHEMBL11381442 0.78 HTT (0.50) ALDH1A1HTTKMT2ANTRK1CDK2
SCHEMBL11373513 0.75 HTT (0.47) ALDH1A1HTTKMT2ANTRK1CDK2
SCHEMBL1122961 0.74 BRAF (0.53) ALDH1A1HTTKMT2ANTRK1PTGS1
SCHEMBL18796141 0.74 HTT (1.00) ALDH1A1HTTKMT2AIDO1MAP4K4
SCHEMBL1122144 0.73 BRAF (0.54) ALDH1A1HTTKMT2AHPGD
SCHEMBL1122251 0.72 HTT (0.44) ALDH1A1HTTKMT2ANTRK1CDK2
SCHEMBL1122587 0.72 BRAF (0.55) ALDH1A1HTTNTRK1LMNA
SCHEMBL29387257 0.71 MEN1 (0.50) ALDH1A1HTTKMT2ANTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831184-B1 PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS WELLCOME TRUST LTD (GB) 2011-02-09 EP disclosed
EP-1831184-B1 PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS WELLCOME TRUST LTD (GB) 2011-02-09 EP disclosed
US-7737152-B2 6-carboaryl-oxy-pyrazin-2-yl-carboaryl-amines and compositions comprising said compounds THE WELLCOME TRUST LIMITED (GB) 2010-06-15 US disclosed
US-20080015191-A1 Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds THE WELLCOME TRUST LIMITED (UK) 2008-01-17 US disclosed
US-20080015191-A1 Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds THE WELLCOME TRUST LIMITED (UK) 2008-01-17 US disclosed
US-20080015191-A1 Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds THE WELLCOME TRUST LIMITED (UK) 2008-01-17 US disclosed
EP-1831184-A2 PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS The Wellcome Trust Limited (GB) 2007-09-12 EP disclosed
WO-2006067466-A2 PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS THE WELLCOME TRUST LIMITED (GB) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015191-A1 Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds BRAF, RAF1, BCOR ALDH1A1 1620/4885HTT 4296/4885KMT2A 2377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.